Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...

Doctors Recommend These Remedies to Get Rid of Phlegm

The best ways to get rid of phlegm, from using nasal sprays to taking the right OTC medications. Plus, they explain what ...

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...

Air Quality in Guna

What's Polluting Delhi's Air? Air Pollution Real-Time Check Air Quality Index, Air Pollution Level, Air Pollution News and all you need to know about Air Quality and Weather Forecasting at news18.com ...
News4JAX

Jacksonville faces severe drought: meteorologist Katie Garner details heat and water concerns

Jacksonville continues to see exceptional drought conditions with a significant rainfall deficit. Meteorologist Katie Garner ...

Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders

Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...
The Manila Times

Beat the heat, stay cool

As summer temperatures rise, it’s tempting to get caught up in outdoor activities. But there are risks. Heat isn’t just ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

Air Quality in Mysuru

What's Polluting Delhi's Air? Air Pollution Real-Time Check Air Quality Index, Air Pollution Level, Air Pollution News and all you need to know about Air Quality and Weather Forecasting at news18.com ...

Saphnelo® subcutaneous approved in Canada for the treatment of systemic lupus erythematosus

CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a ...